Onconetix (NASDAQ:ONCO – Get Free Report) posted its quarterly earnings data on Monday. The company reported ($76.01) EPS for the quarter, beating the consensus estimate of ($45,050.00) by $44,973.99, FiscalAI reports. The business had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million. Onconetix had a negative net margin of 1,575.89% and a negative return on equity of 91.95%.
Onconetix Price Performance
ONCO opened at $3.00 on Wednesday. Onconetix has a 12 month low of $2.76 and a 12 month high of $1,610.00. The business has a fifty day moving average price of $5.99 and a 200 day moving average price of $102.80.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on ONCO shares. Weiss Ratings raised shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, October 29th. Wall Street Zen upgraded shares of Onconetix from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.
Get Our Latest Research Report on Onconetix
About Onconetix
Onconetix, Inc. is a biotechnology company focused on cancer-related diagnostics and therapeutics, with an emphasis on prostate health. Its portfolio includes Proclarix, a blood-based diagnostic test developed to help assess prostate cancer risk. Proclarix was developed by Swiss company Proteomedix, which Onconetix acquired in 2023. The test has received a CE mark for use in Europe; its availability and regulatory status may differ in other markets. Onconetix was formerly known as Blue Water Biotech before adopting its current name in 2024.
Featured Stories
- Five stocks we like better than Onconetix
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Onconetix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconetix and related companies with MarketBeat.com's FREE daily email newsletter.
